Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of participants able to collect equal to or more than 8 x 10\^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10\^6 CD34+ cells/kg are defined as normal mobilizers.

All participants that went on study

→

primary · POSTED

The number of participants of patients who receive greater than or equal to 8 x 10\^6 CD34+ cells/kg following collection with plerixafor, etoposide, and filgrastim and that have progression-free survival at one year

Number of supermobilizer participants that were able to achieve collection of ≥ 8 x 106 CD34+ cells/kg

→

primary · POSTED

Number of participants who receive greater than or equal to 8 x 10\^6 CD34+ cells/kg by 15% following collection with plerixafor, etoposide, and filgrastimstill alive at 1 yr post transplant

Number of supermobilizer participants that were able to achieve collection of ≥ 8 x 106 CD34+ cells/kg

→

secondary · POSTED

Neutrophil recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg entered as the mean cell count of super mobilizers and normal mobilizers.

All participants that had some mobilization

→

secondary · POSTED

Platelet recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg.

All participants that had some mobilization

→

secondary · POSTED

Length of hospital stay in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg.

All participants that had some mobilization

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-t-cell-large-granular-lymphocyte-leukemia
nct id: NCT01408043
trial label: Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0000
source section id
NCT01408043-om-0000
source outcome index
0
endpoint
Collection Using Plerixafor, Etoposide, and Filgrastim
endpoint definition
Number of participants able to collect equal to or more than 8 x 10\^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10\^6 CD34+ cells/kg are defined as normal mobilizers.
time origin
Within 2 days of apheresis
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
All participants that went on study
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0001
source section id
NCT01408043-om-0001
source outcome index
1
endpoint
Progression-free Survival
endpoint definition
The number of participants of patients who receive greater than or equal to 8 x 10\^6 CD34+ cells/kg following collection with plerixafor, etoposide, and filgrastim and that have progression-free survival at one year
time origin
Up to 1 year post-transplant
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Number of supermobilizer participants that were able to achieve collection of ≥ 8 x 106 CD34+ cells/kg
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0002
source section id
NCT01408043-om-0002
source outcome index
2
endpoint
Overall Survival
endpoint definition
Number of participants who receive greater than or equal to 8 x 10\^6 CD34+ cells/kg by 15% following collection with plerixafor, etoposide, and filgrastimstill alive at 1 yr post transplant
time origin
Up to 1 year post-transplant
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Number of supermobilizer participants that were able to achieve collection of ≥ 8 x 106 CD34+ cells/kg
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0003
source section id
NCT01408043-om-0003
source outcome index
3
endpoint
Neutrophil Recovery in Super Mobilizers and Normal Mobilizers
endpoint definition
Neutrophil recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg entered as the mean cell count of super mobilizers and normal mobilizers.
time origin
Up to 28 days post treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All participants that had some mobilization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0004
source section id
NCT01408043-om-0004
source outcome index
4
endpoint
Platelet Recovery in Super Mobilizers and Normal Mobilizers
endpoint definition
Platelet recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg.
time origin
Up to 28 days post treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All participants that had some mobilization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0005
source section id
NCT01408043-om-0005
source outcome index
5
endpoint
Length of Hospital Stay in Super Mobilizers and Normal Mobilizers
endpoint definition
Length of hospital stay in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg.
time origin
Up to 28 days post treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All participants that had some mobilization
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0000
arm key
OG000
arm label
Treatment (Stem Cell Supermobilization)
regimen
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
analyzed count
25
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01408043-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0001
arm key
OG000
arm label
Treatment (Stem Cell Supermobilization)
regimen
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
analyzed count
7
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01408043-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0002
arm key
OG000
arm label
Treatment (Stem Cell Supermobilization)
regimen
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
analyzed count
7
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01408043-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0003
arm key
OG000
arm label
Treatment (Stem Cell Supermobilization)
regimen
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
analyzed count
24
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01408043-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0004
arm key
OG000
arm label
Treatment (Stem Cell Supermobilization)
regimen
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
analyzed count
24
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01408043-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
outcome key
om-0005
arm key
OG000
arm label
Treatment (Stem Cell Supermobilization)
regimen
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
analyzed count
24
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01408043-om-0005#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-t-cell-large-granular-lymphocyte-leukemia
nct id
NCT01408043
harm key
EG000
source section id
NCT01408043-ae
event group key
EG000
event group label
Treatment (Stem Cell Supermobilization)
serious affected
0
serious at risk
25
other affected
0
other at risk
25
frequency threshold
5
collection period
Up to 1 year post-transplant
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice